• Explore /
  • Poster
  • / A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients with metastatic melanoma (MM).

A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients with metastatic melanoma (MM).

Abstract Poster

Authors

null

Emily Keung

The University of Texas MD Anderson Cancer Center, Houston, TX

Emily Keung , Elizabeth M. Burton , Rodabe Navroze Amaria , Isabella Claudia Glitza , Sapna Pradyuman Patel , Adi Diab , Cassian Yee , Michael K Wong , Wen-Jen Hwu , Patrick Hwu , Scott Eric Woodman , Michael T. Tetzlaff , Denai Milton , Kristen Perez , Michael A. Davies , Kunal Rai , Jennifer Ann Wargo , Hussein Abdul-Hassan Tawbi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02816021

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS9594)

DOI

10.1200/JCO.2017.35.15_suppl.TPS9594

Abstract #

TPS9594

Poster Bd #

200b

Abstract Disclosures

Similar Posters

First Author: Elizabeth M. Burton

First Author: Hussein Abdul-Hassan Tawbi

First Author: Timothy Jay Price

First Author: Samuel J Klempner